Lv1
18 积分 2021-10-04 加入
A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis
1个月前
已完结
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
1个月前
已完结
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
1个月前
已完结
Single-cell and clonal analysis of AL amyloidosis plasma cells and their bone marrow microenvironment
1个月前
已完结
CD38: A multi-lineage cell activation molecule with a split personality
1个月前
已完结
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
1个月前
已完结
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
3个月前
已完结
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
3个月前
已完结
IgA Nephropathy in Adults
4个月前
已完结
A Comprehensive Review of Marketed KRAS Inhibitors and Degraders: Challenges and Opportunities
4个月前
已完结
皖公网安备34019202002308
